Low-density lipoprotein receptor-related protein 5 (LRP5) expression in human osteoarthritic chondrocytes. 2010

Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
University of Thessaly, Medical School, Laboratory of Cytogenetics and Molecular Genetics, Larissa, Greece.

The aim of this study was to investigate the activation of the Wnt/beta-catenin pathway in osteoarthritis and the role of low-density lipoprotein receptor-related protein 5 (LRP5) in human osteoarthritic chondrocytes. The influence of 1,25(OH)2D3 on the expression of the LRP5 gene in human chondrocytes was also assessed. Human cartilage was obtained from 11 patients with primary osteoarthritis (OA) undergoing total knee replacement surgery. Normal cartilage was obtained from five healthy individuals. Beta-catenin and LRP5 mRNA levels were investigated using real-time PCR and LRP5 protein expression using Western blot analysis. Furthermore, we evaluated the effect of 1,25(OH)2D3 on LRP5 mRNA expression levels in osteoarthritic chondrocytes. Blocking LRP5 expression was performed using small interfering RNA (siRNA) against LRP5, and subsequent MMP-13 mRNA and protein levels were evaluated by real-time PCR and Western blot analysis, respectively. We confirmed the activation of the Wnt/beta-catenin pathway in OA, as we observed significant up-regulation of beta-catenin mRNA expression in osteoarthritic chondrocytes. We also observed that LRP5 mRNA and protein expression were significantly up-regulated in osteoarthritic cartilage compared to normal cartilage, and LRP5 mRNA expression was further increased by vitamin D. Also, blocking LRP5 expression using siRNA against LRP5 resulted in a significant decrease in MMP-13 mRNA and protein expressions. Our findings suggest the catabolic role of LRP5 is mediated by the Wnt/beta-catenin pathway in human osteoarthritis.

UI MeSH Term Description Entries
D008297 Male Males
D010003 Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. Arthritis, Degenerative,Osteoarthrosis,Osteoarthrosis Deformans,Arthroses,Arthrosis,Arthritides, Degenerative,Degenerative Arthritides,Degenerative Arthritis,Osteoarthritides,Osteoarthroses
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002358 Cartilage, Articular A protective layer of firm, flexible cartilage over the articulating ends of bones. It provides a smooth surface for joint movement, protecting the ends of long bones from wear at points of contact. Articular Cartilage,Articular Cartilages,Cartilages, Articular
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
April 2010, Bone,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
February 2002, Human mutation,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
January 2004, Journal of human genetics,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
January 2014, Arthritis research & therapy,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
January 2012, PloS one,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
April 2010, Clinical endocrinology,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
April 2022, Experimental eye research,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
January 2008, Oncogene,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
January 2008, Human heredity,
Ioanna Papathanasiou, and Konstantinos N Malizos, and Aspasia Tsezou
November 2017, Experimental dermatology,
Copied contents to your clipboard!